GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » EV-to-FCF

Biotest AG (Biotest AG) EV-to-FCF : 78.78 (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biotest AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biotest AG's Enterprise Value is $1,989.6 Mil. Biotest AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $25.3 Mil. Therefore, Biotest AG's EV-to-FCF for today is 78.78.

The historical rank and industry rank for Biotest AG's EV-to-FCF or its related term are showing as below:

BIESF' s EV-to-FCF Range Over the Past 10 Years
Min: -845.06   Med: -14.11   Max: 129.44
Current: 80.65

During the past 13 years, the highest EV-to-FCF of Biotest AG was 129.44. The lowest was -845.06. And the median was -14.11.

BIESF's EV-to-FCF is ranked worse than
85.08% of 382 companies
in the Biotechnology industry
Industry Median: 8.405 vs BIESF: 80.65

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-08), Biotest AG's stock price is $30.48. Biotest AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $5.549. Therefore, Biotest AG's PE Ratio for today is 5.49.


Biotest AG EV-to-FCF Historical Data

The historical data trend for Biotest AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG EV-to-FCF Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.01 -34.72 131.75 -30.54 -60.42

Biotest AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.31 -13.71 -17.42 -60.42 68.65

Competitive Comparison of Biotest AG's EV-to-FCF

For the Biotechnology subindustry, Biotest AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biotest AG's EV-to-FCF falls into.



Biotest AG EV-to-FCF Calculation

Biotest AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1989.616/25.254
=78.78

Biotest AG's current Enterprise Value is $1,989.6 Mil.
Biotest AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotest AG  (OTCPK:BIESF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biotest AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=30.48/5.549
=5.49

Biotest AG's share price for today is $30.48.
Biotest AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.549.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biotest AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Biotest AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (Biotest AG) Business Description

Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Biotest AG (Biotest AG) Headlines

From GuruFocus

Q4 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Full Year 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024